You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1/PD-L1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Oct 24, 2023

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

Not yet recruiting
  • Lung Neoplasm
  • +2 more
  • Tumor samples
  • Bordeaux, France
    CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
Aug 28, 2023

NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 29, 2022

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Advanced

Not yet recruiting
  • Carcinoma, Hepatocellular
    • (no location specified)
    May 16, 2022

    Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

    Recruiting
    • Esophageal Neoplasms
    • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
    • Zhengzhou, Henan, China
      The First Affiliated Hospital of Zhengzhou University
    Apr 21, 2022

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Radiotherapy
    • +4 more
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Sep 14, 2023

    Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

    Not yet recruiting
    • Colorectal Cancer Stage IV
    • +2 more
    • (no location specified)
    Jun 19, 2022

    Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b

    Recruiting
    • Hepatocellular Carcinoma
    • Shanghai, China
      Zhongshan Hospital, Fudan University
    Mar 28, 2022

    Oncology, NSCLC Stage IV, NSCLC, Stage III Trial in Drammen (UV1, Sagramostim, Anti-PD-1/PD-L1 treatment)

    Recruiting
    • Oncology
    • +2 more
    • UV1
    • +2 more
    • Drammen, Viken, Norway
      Vestre Viken Health Trust
    Aug 15, 2022

    PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on

    Recruiting
    • Hepatocellular Carcinoma
    • Acute Rejection
      • Beijing, Beijing, China
        Beijing Tsinghua Changgung Hospital
      Jun 6, 2022

      Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Chuo-ku, Tokyo, Japan
        National Cancer Center Hospital ( Site 3700)
      Jan 31, 2023

      Non Small Cell Lung Cancer Trial in Changsha (Anlotinib Plus Penpulimab)

      Recruiting
      • Non Small Cell Lung Cancer
      • Anlotinib Plus Penpulimab
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Jul 17, 2022

      Metastasis, Solid Tumor Trial (Peptide Alarm Therapy (PAT))

      Not yet recruiting
      • Metastasis
      • Solid Tumor
      • Peptide Alarm Therapy (PAT)
      • (no location specified)
      Nov 2, 2022